Never miss the latest news and offers - subscribe now!
Adherent and suspension bioreactors for viral vector manufacturing are evolving. However, for each choice, a robust manufacturing process is critical to ensure it is scalable for these novel therapies to reach the patients.
One of the first steps in designing a process is whether to use adherent or suspension cell cultures. Each modality has its advantages and disadvantages. In this webinar, the panelists will outline key considerations in choosing the right technology and some of the pitfalls that must be overcome to ensure success at large scale.
Participants will learn:
How Andelyn and Pall worked together to scale up an AAV manufacturing process to 500L